- Home
- LTRN vs HURA Comparison
LTRN vs HURA Comparison
Compare LTRN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LTRN | HURA |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 35.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LTRN | HURA |
|---|---|---|
| Price | $2.56 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $25.00 | $10.00 |
| AVG Volume (30 Days) | 46.6K | ★ 3.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $0.41 |
| 52 Week High | $5.74 | $4.41 |
Technical Indicators
Market Signals| Indicator | LTRN | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 68.39 |
| Support Level | $2.53 | $0.70 |
| Resistance Level | $3.65 | $1.55 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 19.23 | 81.37 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.